Default company panoramic image
5087402e 2871 4412 b3c5 e8012ea4bbc0

Nanoscan Imaging, LLC

NanoScan’s platform technologies promise to change in the way MDs view cancer, cardiovascular disease, autoimmune and neurogenic disorders

  • Stage Product In Development
  • Industry Medical Devices and Equipment
  • Location Lansdale, PA, USA
  • Currency USD
  • Founded August 2005
  • Employees 4
  • Website

Company Summary

NanoScan Imaging (“NSI”) was formed to continue the development of N1177, a reimbursable CT contrast agent that will change the way MDs view cancer and CVD.. Our management team and BOD have rich backgrounds in the technology. N1177’s clinically experienced platform targets the $5.3 B radiopharmaceutical market, has an open IND and IP protection through 2028. NSI is talking to acquisition candidates and plans to sell N1177 in 2-3 years.


  • Default avatar
    Don Skerrett

    Don is President of PCCI, a professional association that helps early-stage life science companies succeed. His areas of expertise include strategic healthcare marketing, business intelligence, reimbursement, the nursing crisis, the DME market, medical devices, hospital asset management, and the development of strategic business alliances. He has founded and run several companies in addition to Corporate Development Advisors.

  • Default avatar
    Linda Nardone
    VP Regulatory Affairs

    Linda is an accomplished senior drug development and operations executive with documented success coordinating drug and biologics development, such as Omnipaque®, Omniscan®, Bexxar®, and Protonix® throughout all regulatory and clinical phases (from early stage investigation and proof of concept to completion of clinical trials, FDA approval, and post-marketing) for pharmaceutical, biotechnology and clinical CRO organizations.

  • Default avatar
    Mark Carvlin
    Proposed VP Development

    Mark was Senior Director of Product Development at Bracco Diagnostics, Senior Market Manager of Magnetic Resonance Products at Bristol-Myers Squibb Diagnostics, a faculty member of the Department of Radiology at the University of Pennsylvania and Georgetown University.

  • Default avatar
    Peter van der Kam

    Peter's Pharmaceutical Industry credits include positions with Merck in Spain (New Products Manager), Venezuela (Marketing Director), and the United States (International Group Manager Cardiovasculars), and with Wyeth in Spain (Deputy General Manager) and in the United States (Group Director European Operations).